Bristol-Myers Squibb Company (NYSE:BMY) : The most positive equity analysts on Bristol-Myers Squibb Company (NYSE:BMY) expects the shares to touch $100, whereas, the least positive believes that the stock will trade at $48 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $73.64 with an expected fluctuation of $13.61 from the mean.
Other Equity analysts have also commented on the company shares. Jefferies maintains its rating on Bristol-Myers Squibb Company (NYSE:BMY). The global brokerage major raises the current price target from $76 per share to $78 per share. Analysts at the Jefferies have a current rating of Hold on the shares. The rating by the firm was issued on June 14, 2016.
Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Thursday. Though the stock opened at $72.86, the bulls momentum made the stock top out at $72.91 level for the day. The stock recorded a low of $72.15 and closed the trading day at $72.64, in the green by 0.46%. The total traded volume for the day was 5,624,535. The stock had closed at $72.31 in the previous days trading.
The company shares have rallied 8.18% from its 1 Year high price. On Jun 6, 2016, the shares registered one year high at $75.12 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $71.75 and the 200 Day Moving Average price is recorded at $67.00. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Elicker John E, officer (SVP, Public Affairs & IR) of Bristol Myers Squibb Co, had unloaded 11,820 shares at an average price of $72.69 in a transaction dated on June 14, 2016. The total value of the transaction was worth $859,196.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.